^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR2 (Fibroblast growth factor receptor 2)

    i
    Apply
    Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/07/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • FGFR2 • NECTIN4
    |
    PD-L1 expression
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) (NCT04083976)
    Phase 2
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/20/2019
    Primary completion :
    12/04/2023
    Completion :
    12/31/2025
    FGFR2 • FGFR • TACC3 • TACC2
    |
    FGFR3 mutation • FGFR mutation • FGFR fusion
    |
    Balversa (erdafitinib)
    A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (NCT04238715)
    Phase 2
    Eisai Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    01/22/2020
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    FGFR2
    |
    FGFR2 fusion
    |
    cisplatin • Tasfygo (tasurgratinib)
    Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) (NCT05052801)
    Phase 3
    Amgen
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/07/2022
    Primary completion :
    08/18/2025
    Completion :
    08/18/2025
    FGFR2
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    Futibatinib in Patients With Specific FGFR Aberrations (TAS-120-202) (NCT04189445)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/24/2020
    Primary completion :
    11/11/2024
    Completion :
    03/31/2025
    FGFR2
    |
    FGFR2 amplification • FGFR1 rearrangement
    |
    Lytgobi (futibatinib)
    Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) (NCT01505400)
    Phase N/A
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/01/2012
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1
    Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4) (NCT05727176)
    Phase 2
    Taiho Oncology, Inc.
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    07/05/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    FGFR2
    |
    FGFR2 fusion • FGFR2 rearrangement
    |
    Lytgobi (futibatinib)
    REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors (ReFocus) (NCT04526106)
    Phase 1/2
    Elevar Therapeutics
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/02/2020
    Primary completion :
    09/27/2024
    Completion :
    12/01/2027
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion
    |
    lirafugratinib (RLY-4008)
    A Phase 2 Clinical Study of ABSK061 and ABSK043 (NCT06632262)
    Phase 2
    Abbisko Therapeutics Co, Ltd
    Recruiting
    Last update posted :
    11/19/2024
    Initiation :
    11/13/2024
    Primary completion :
    11/30/2029
    Completion :
    06/30/2030
    HER-2 • FGFR2 • FGFR3
    |
    ABSK043 • ABSK061
    Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements (NCT05174650)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Active, not recruiting
    Last update posted :
    07/24/2024
    Initiation :
    04/20/2022
    Primary completion :
    12/01/2025
    Completion :
    08/01/2026
    FGFR2
    |
    FGFR2 fusion
    |
    Tecentriq (atezolizumab) • derazantinib (ARQ 087)
    Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) (NCT05948475)
    Phase 3
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/20/2023
    Primary completion :
    05/01/2026
    Completion :
    08/01/2026
    FGFR2
    |
    FGFR2 fusion
    |
    5-fluorouracil • irinotecan • tinengotinib (TT-00420)
    Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102) (NCT05111626)
    Phase 3
    Amgen
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    03/14/2022
    Primary completion :
    09/26/2026
    Completion :
    09/26/2026
    FGFR2
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement (CIBI375A201) (NCT04256980)
    Phase 2
    Innovent Biologics (Suzhou) Co. Ltd.
    Completed
    Last update posted :
    05/30/2024
    Initiation :
    03/03/2020
    Primary completion :
    01/29/2021
    Completion :
    08/31/2023
    FGFR2
    |
    FGFR2 rearrangement
    |
    Pemazyre (pemigatinib)
    A Study of TAS-120 in Patients With Metastatic Breast Cancer (FOENIX-MBC2 TAS-120-201) (NCT04024436)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/30/2019
    Primary completion :
    05/31/2023
    Completion :
    07/05/2024
    HER-2 • PD-L1 • FGFR2
    |
    HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification
    |
    fulvestrant • Lytgobi (futibatinib)
    A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302) (NCT03656536)
    Phase 3
    Incyte Corporation
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    06/03/2019
    Primary completion :
    10/26/2027
    Completion :
    07/27/2028
    FGFR2
    |
    FGFR2 rearrangement
    |
    cisplatin • gemcitabine • Pemazyre (pemigatinib)
    XmAb20717 in Advanced Biliary Tract Cancers (NCT05297903)
    Phase 2
    Abramson Cancer Center at Penn Medicine
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/11/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    FGFR2 • IDH1 • NTRK
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion
    |
    vudalimab (XmAb717)
    A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations (NCT05242822)
    Phase 1
    Kinnate Biopharma
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    04/18/2022
    Primary completion :
    06/01/2026
    Completion :
    09/01/2026
    FGFR2
    |
    KIN-3248
    Pemigatinib + Afatinib in Advanced Refractory Solid Tumors (NCT06302621)
    Phase 1
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    07/01/2024
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    FGFR2
    |
    Gilotrif (afatinib) • Pemazyre (pemigatinib)
    Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma (NCT04919642)
    Phase 2
    TransThera Sciences (Nanjing), Inc.
    Completed
    Last update posted :
    04/26/2024
    Initiation :
    12/07/2021
    Primary completion :
    02/28/2024
    Completion :
    02/28/2024
    FGFR2 • FGFR
    |
    FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type
    |
    tinengotinib (TT-00420)
    Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (NCT04641871)
    Phase 1
    Symphogen A/S
    Active, not recruiting
    Last update posted :
    04/24/2024
    Initiation :
    10/12/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    FGFR2 • IDH1
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion
    |
    irinotecan • S95018 • Sym021 • Sym022
    A Study of TAS-120 in Patients With Advanced Solid Tumors (FOENIX-CCA2) (NCT02052778)
    Phase 1/2
    Taiho Oncology, Inc.
    Completed
    Last update posted :
    03/20/2024
    Initiation :
    07/21/2014
    Primary completion :
    10/01/2020
    Completion :
    05/29/2021
    FGFR2
    |
    FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion
    |
    Lytgobi (futibatinib)
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774)
    Phase N/A
    Massive Bio, Inc.
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    01/01/2018
    Primary completion :
    12/01/2026
    Completion :
    06/01/2027
    EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (NCT03694522)
    Phase 2
    Five Prime Therapeutics, Inc.
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/14/2018
    Primary completion :
    09/23/2020
    Completion :
    05/13/2022
    FGFR2
    |
    FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (NCT04507503)
    Phase N/A
    Taiho Oncology, Inc.
    Approved for marketing
    Last update posted :
    02/23/2024
    FGFR2
    |
    FGFR2 rearrangement
    |
    Lytgobi (futibatinib)
    A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma (NCT05678270)
    Phase 2
    Beijing InnoCare Pharma Tech Co., Ltd.
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    11/15/2022
    Primary completion :
    05/01/2026
    Completion :
    12/01/2026
    FGFR2
    |
    FGFR2 fusion
    |
    gunagratinib (ICP-192)
    Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (NCT03238196)
    Phase 1
    Vanderbilt-Ingram Cancer Center
    Active, not recruiting
    Last update posted :
    02/01/2024
    Initiation :
    08/18/2017
    Primary completion :
    04/30/2021
    Completion :
    09/25/2024
    HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23
    |
    HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification
    |
    Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant
    Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (NCT05267106)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    01/19/2024
    Initiation :
    05/20/2022
    Primary completion :
    11/29/2024
    Completion :
    11/29/2024
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement
    |
    Pemazyre (pemigatinib)
    NCCH2006/MK010 Trial (FORTUNE Trial) (NCT04962867)
    Phase 2
    National Cancer Center, Japan
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    06/15/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK
    |
    EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation
    |
    Tasfygo (tasurgratinib)
    To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053)
    Phase 1/2
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    01/03/2024
    Initiation :
    04/13/2022
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    HER-2 • FGFR2
    |
    PD-L1 expression • HER-2 negative
    |
    Tecentriq (atezolizumab) • albumin-bound paclitaxel • tinengotinib (TT-00420)
    Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2) (NCT05859477)
    Phase 2
    Kidney Cancer Research Bureau
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    06/05/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    HER-2 • PD-L1 • FGFR2
    |
    HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression
    |
    Opdivo (nivolumab) • capecitabine • oxaliplatin
    Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor (NCT06057571)
    Phase 2
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    11/17/2023
    Primary completion :
    06/15/2025
    Completion :
    10/31/2025
    FGFR2
    |
    tinengotinib (TT-00420)
    Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors (PERIO-02) (NCT05220722)
    Phase 1/2
    TriSalus Life Sciences, Inc.
    Active, not recruiting
    Last update posted :
    12/25/2023
    Initiation :
    03/02/2022
    Primary completion :
    12/01/2023
    Completion :
    01/01/2025
    FGFR2
    |
    FGFR2 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • nelitolimod (SD-101)
    Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) (NCT03230318)
    Phase 2
    Basilea Pharmaceutica
    Completed
    Last update posted :
    12/19/2023
    Initiation :
    09/28/2017
    Primary completion :
    10/25/2022
    Completion :
    10/25/2022
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion
    |
    derazantinib (ARQ 087)
    Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02) (NCT04045613)
    Phase 1b/2
    Basilea Pharmaceutica
    Completed
    Last update posted :
    10/13/2023
    Initiation :
    08/02/2019
    Primary completion :
    10/04/2022
    Completion :
    10/04/2022
    FGFR2
    |
    FGFR2 mutation • FGFR3 mutation
    |
    Tecentriq (atezolizumab) • derazantinib (ARQ 087)
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (NCT05627063)
    Phase 1
    Abbisko Therapeutics Co, Ltd
    Recruiting
    Last update posted :
    09/01/2023
    Initiation :
    06/26/2023
    Primary completion :
    03/15/2025
    Completion :
    06/30/2025
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C
    |
    ABSK121
    Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements (NCT05565794)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    11/11/2022
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    FGFR2 • CD4
    |
    FGFR2 fusion
    |
    Pemazyre (pemigatinib)
    Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification (NCT05510427)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    08/15/2023
    Initiation :
    08/07/2023
    Primary completion :
    08/07/2023
    Completion :
    08/07/2023
    FGFR2 • CD4
    |
    FGFR2 fusion
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Truseltiq (infigratinib)
    Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer (NCT05991947)
    Phase N/A
    Zhejiang Cancer Hospital
    Recruiting
    Last update posted :
    08/15/2023
    Initiation :
    12/01/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A
    |
    KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation